These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 23646111)
41. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility. Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553 [TBL] [Abstract][Full Text] [Related]
42. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. Diaz CM; Segura ER; Luz PM; Clark JL; Ribeiro SR; De Boni R; Eksterman L; Moreira R; Currier JS; Veloso VG; Grinsztejn B; Lake JE BMC Infect Dis; 2016 Aug; 16():376. PubMed ID: 27503230 [TBL] [Abstract][Full Text] [Related]
43. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516 [TBL] [Abstract][Full Text] [Related]
44. Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy. Stöhr W; Dunn DT; Arenas-Pinto A; Orkin C; Clarke A; Williams I; Johnson M; Beeching NJ; Wilkins E; Sanders K; Paton NI; AIDS; 2016 Nov; 30(17):2617-2624. PubMed ID: 27456983 [TBL] [Abstract][Full Text] [Related]
45. Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects. Vergori A; Pinnetti C; Lorenzini P; Brita A; Libertone R; Mastrorosa I; Cicalini S; Antinori A; Ammassari A Infection; 2019 Dec; 47(6):929-935. PubMed ID: 31183805 [TBL] [Abstract][Full Text] [Related]
46. Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation. Eckard AR; Rosebush JC; O'Riordan MA; Graves CC; Alexander A; Grover AK; Lee ST; Habib JG; Ruff JH; Chahroudi A; McComsey GA Antivir Ther; 2017; 22(8):669-680. PubMed ID: 28327462 [TBL] [Abstract][Full Text] [Related]
47. Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection. Lopardo GD; Bissio E; Iannella Mdel C; Crespo AD; Garone DB; Cassetti LI J Acquir Immune Defic Syndr; 2009 Dec; 52(4):488-92. PubMed ID: 19654553 [TBL] [Abstract][Full Text] [Related]
48. Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Ellis RJ; Sacktor N; Clifford DB; Marra CM; Collier AC; Gelman B; Robinson-Papp J; Letendre SL; Heaton RK; Brain; 2022 Jun; 145(6):2206-2213. PubMed ID: 35773234 [TBL] [Abstract][Full Text] [Related]
49. HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms? Payne BA; Hateley CL; Ong EL; Premchand N; Schmid ML; Schwab U; Newton JL; Price DA HIV Med; 2013 Apr; 14(4):247-51. PubMed ID: 22998022 [TBL] [Abstract][Full Text] [Related]
50. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil. Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557 [TBL] [Abstract][Full Text] [Related]
51. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. Gianotti N; Cozzi-Lepri A; Antinori A; Castagna A; De Luca A; Celesia BM; Galli M; Mussini C; Pinnetti C; Spagnuolo V; d'Arminio Monforte A; Ceccherini-Silberstein F; Andreoni M; PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453 [TBL] [Abstract][Full Text] [Related]
52. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384 [TBL] [Abstract][Full Text] [Related]
53. Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning? Muñoz-Moreno JA; Fumaz CR; Prats A; Ferrer MJ; Negredo E; Pérez-Alvarez N; Moltó J; Gómez G; Garolera M; Clotet B J Neurovirol; 2010 May; 16(3):208-18. PubMed ID: 20450380 [TBL] [Abstract][Full Text] [Related]
54. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study. Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166 [TBL] [Abstract][Full Text] [Related]
55. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure. Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738 [TBL] [Abstract][Full Text] [Related]
56. Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. Arenas-Pinto A; Winston A; Stöhr W; Day J; Wiggins R; Quah SP; Ainsworth J; Fleck S; Dunn D; Accoroni A; Paton NI; PLoS One; 2014; 9(7):e103498. PubMed ID: 25078406 [TBL] [Abstract][Full Text] [Related]
57. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. McCombe JA; Vivithanaporn P; Gill MJ; Power C HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556 [TBL] [Abstract][Full Text] [Related]
58. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. Ho JE; Deeks SG; Hecht FM; Xie Y; Schnell A; Martin JN; Ganz P; Hsue PY AIDS; 2010 Jul; 24(12):1897-905. PubMed ID: 20543654 [TBL] [Abstract][Full Text] [Related]
59. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Jeremy RJ; Kim S; Nozyce M; Nachman S; McIntosh K; Pelton SI; Yogev R; Wiznia A; Johnson GM; Krogstad P; Stanley K; Pediatrics; 2005 Feb; 115(2):380-7. PubMed ID: 15687448 [TBL] [Abstract][Full Text] [Related]
60. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. Antinori A; Arribas J; Fehr J; Girard PM; Horban A; Hill A; van Delft Y; Moecklinghoff C; Hill A J Int AIDS Soc; 2014; 17(4 Suppl 3):19525. PubMed ID: 25394034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]